Literature DB >> 17564870

Public opinion on needle and syringe programmes: avoiding assumptions for policy and practice.

Carla Treloar1, Suzanne Fraser.   

Abstract

Despite evidence for their effectiveness, harm reduction services such as needle and syringe programmes (NSPs) are highly vulnerable to perceptions of community disapproval. This paper reviews Australian research on community attitudes to harm reduction services and its impact on research, policy and practice. The literature on community attitudes to NSPs in Australia comprises a small number of representative national samples and surveys of local communities affected by specific services. Despite these extremely limited data, negative community attitudes are often cited by policy-makers and health professionals as a primary constraint on policy-making. The main finding of this literature review is that community perceptions of NSPs are largely positive. Also, support for NSPs was not synonymous with condoning drug use. The failure of policy-makers and politicians to recognise positive community attitudes to NSPs has led in some instances to hasty political responses to adverse media reports, including the closure of services. This literature review showing positive community attitudes to harm reduction services should embolden researchers, practitioners and policy-makers to challenge such reactionary responses. Further, this evidence should be used in countering negative publicity surrounding these services.

Mesh:

Year:  2007        PMID: 17564870     DOI: 10.1080/09595230701373867

Source DB:  PubMed          Journal:  Drug Alcohol Rev        ISSN: 0959-5236


  2 in total

1.  Message framing to reduce stigma and increase support for policies to improve the wellbeing of people with prior drug convictions.

Authors:  Sachini N Bandara; Emma E McGinty; Colleen L Barry
Journal:  Int J Drug Policy       Date:  2020-01-07

2.  Provision of opioid substitution therapy services in Australian pharmacies.

Authors:  B B Chaar; J R Hanrahan; C Day
Journal:  Australas Med J       Date:  2011-04-30
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.